SOPHiA Genetics Chairman Sells 8,500 Shares Amid Quarterly Loss
Chairman Jurgi Camblong executed a scheduled sale of 8,500 SOPHiA Genetics shares at an average price of $7.66, reducing his stake while the company reported a quarterly EPS miss of $0.05.
SOPHiA Genetics SA (NASDAQ:SOPH) disclosed on September 10 that Chairman Jurgi Camblong sold 8,500 shares of common stock at an average price of $7.66. The transaction, valued at $65,110, was executed under a pre-arranged Rule 10b5-1 trading plan and resulted in a 0.25% reduction in his total ownership. Following the sale, Camblong retained 3,435,822 shares, representing a position valued at approximately $26.32 million based on the prevailing market price.
This latest disposal continues a consistent pattern of insider liquidity events over the preceding quarter. Between June 25 and September 10, the chairman executed ten separate sales transactions, offloading a cumulative total of 172,514 shares. The average execution price for these trades ranged from $5.25 to $7.66, indicating the chairman capitalized on the stock's recent appreciation from its twelve-month low of $3.12.
Quarterly Financial Results
SOPHiA Genetics reported its second-quarter earnings on August 5, revealing a loss per share of $0.26 against a consensus estimate of $0.21. The company generated revenue of $23.31 million, exceeding the analyst forecast of $21.72 million by 7.3%. Despite the top-line beat, the company recorded a negative net margin of 93.86% and a negative return on equity of 132.47%, reflecting ongoing operational pressures that have kept the stock's price-to-earnings ratio negative at -6.83.
The balance sheet remains stable with a current ratio of 2.69 and a quick ratio of 2.55, providing sufficient liquidity to cover short-term obligations. The debt-to-equity ratio stands at 0.58, while the beta of 0.98 suggests the equity moves in line with broader market indices. These financial metrics were cited by sell-side analysts when adjusting their valuation models following the earnings release.
Market Valuation and Analyst Outlook
As reported by GN stocks/nasdaq, the company’s market capitalization is currently valued at $659.38 million. The stock recently traded at $7.86, down $0.01 from the previous session, with volume of 309,330 shares exceeding the average of 261,716. Technical indicators show the fifty-day moving average at $7.03 and the 200-day moving average at $5.69, positioning the current price well above both benchmarks and near the twelve-month high of $8.98.
Analyst sentiment remains divided regarding the forward trajectory. HC Wainwright raised its price target from $12.00 to $14.00 and maintained a buy rating, while BTIG Research increased its objective from $8.00 to $9.00. Conversely, Weiss Ratings reiterated a sell rating with a D- score on July 17. For the current fiscal year, sell-side consensus projects an EPS of negative $0.77, indicating that profitability concerns persist despite the recent revenue outperformance.
